Hologic (HOLX) to Release Quarterly Earnings on Monday

Hologic (NASDAQ:HOLX) is scheduled to post its quarterly earnings results after the market closes on Monday, November 4th. Analysts expect Hologic to post earnings of $1.02 per share for the quarter. Individual that wish to register for the company’s earnings conference call can do so using this link.

Hologic Stock Up 1.8 %

HOLX stock opened at $82.33 on Friday. Hologic has a 1-year low of $66.53 and a 1-year high of $84.67. The business’s 50 day simple moving average is $80.99 and its 200 day simple moving average is $77.98. The company has a current ratio of 3.99, a quick ratio of 3.32 and a debt-to-equity ratio of 0.51. The firm has a market capitalization of $19.12 billion, a PE ratio of 28.00, a PEG ratio of 2.93 and a beta of 0.98.

Insiders Place Their Bets

In other news, insider Brandon Schnittker sold 476 shares of the business’s stock in a transaction that occurred on Tuesday, August 6th. The shares were sold at an average price of $83.11, for a total value of $39,560.36. Following the completion of the transaction, the insider now directly owns 3,735 shares in the company, valued at approximately $310,415.85. The trade was a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 1.75% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on the stock. Evercore ISI increased their price objective on shares of Hologic from $78.00 to $82.00 and gave the company an “in-line” rating in a research report on Tuesday, October 1st. Leerink Partners lowered their price target on shares of Hologic from $95.00 to $90.00 and set an “outperform” rating on the stock in a report on Tuesday, October 8th. JPMorgan Chase & Co. boosted their price objective on Hologic from $91.00 to $95.00 and gave the stock an “overweight” rating in a report on Tuesday, July 30th. Needham & Company LLC reiterated a “buy” rating and set a $90.00 target price on shares of Hologic in a research note on Tuesday, October 15th. Finally, StockNews.com downgraded Hologic from a “strong-buy” rating to a “buy” rating in a research note on Friday, September 27th. Five investment analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company. According to data from MarketBeat.com, Hologic presently has a consensus rating of “Moderate Buy” and an average price target of $87.50.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.